%PDF-1.4
%
51 0 obj
<>
endobj
48 0 obj
<>
endobj
113 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2003-03-05T14:17:30Z
2024-03-29T06:07:28-07:00
QuarkXPressª 4.11: AdobePS 8.6 (219)
2024-03-29T06:07:28-07:00
application/pdf
Heather
2002-85.May
uuid:1bbed928-1dd2-11b2-0a00-8e09275dc400
uuid:1bbed92b-1dd2-11b2-0a00-810000000000
endstream
endobj
37 0 obj
<>
endobj
38 0 obj
<>
endobj
52 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
4 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
7 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
10 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
13 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
16 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
19 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
22 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
25 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
151 0 obj
[155 0 R]
endobj
152 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
/CS0 cs 0 0 0 1 scn
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 74.4 714.5293 Tm
(questionnaire and correlation with anthropometic variables. Br J)Tj
0 -1.25 TD
(Rheumatol 1994;33:1060-6.)Tj
-2.175 -1.25 Td
[(29.)-875.1 (Dziedzic KSG. )17.7 (The body chart: )54.8 (A)-220.1 (further sketch towards a fuller)]TJ
2.175 -1.25 Td
[(picture of ankylosing spondylitis [PhD thesis]. Staf)17.7 (fordshire:)]TJ
T*
(University of Keele; 1997, 251 p.)Tj
-2.175 -1.25 Td
[(30.)-875.1 (EuroQol Group. EuroQol: a new facility for the measurement of)]TJ
2.175 -1.25 Td
(health-related quality of life. Health Policy 1990;16:199-208.)Tj
-2.175 -1.25 Td
[(31.)-875.1 (W)79.9 (are JE, Kosinski M, Keller SD. SF-12: How to score the SF-12)]TJ
2.175 -1.25 Td
[(physical and mental health summary scales. Boston: )17.7 (The Health)]TJ
T*
(Institute, New England Medical Centre; 1995.)Tj
-2.175 -1.25 Td
[(32.)-875.1 (Hurst NP)110.7 (, Kind P)110.7 (, Ruta D, Hunter M, Stubbings )54.8 (A. Measuring)]TJ
2.175 -1.25 Td
[(health-related quality of life in rheumatoid arthritis: validity)64.8 (,)]TJ
T*
(responsiveness and reliability of EuroQol \(EQ-5D\). Br J Rheumatol)Tj
0 Tc 0 Tw T*
(1997;36:551-9.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(33.)-875.1 (Hurst NP)110.7 (, Ruta DA, Kind P)110.7 (. Comparison of the MOS Short )]TJ
2.175 -1.25 Td
(Form-12 \(SF-12\) health status questionnaire with the SF-36 in)Tj
T*
(patients with rheumatoid arthritis. Br J Rhematol 1998;37:62-9.)Tj
-2.175 -1.25 Td
[(34.)-875.1 (Deyo RA, Diehr P)110.7 (, Patrick DL. Reproducibility and responsiveness)]TJ
2.175 -1.25 Td
(of health status measures. Statistics and strategies for evaluation.)Tj
T*
[(Controlled Clin )17.7 (T)35 (rials 1991;12:142S-58S.)]TJ
-2.175 -1.25 Td
[(35.)-875.1 (Fitzpatrick R, Zieblans S, Jenkinson C, Mowat )54.8 (A. )17.7 (T)35 (ransition )]TJ
2.175 -1.25 Td
(questions to assess outcomes in rheumatoid arthritis. Br J)Tj
T*
[(Rheumatol 1993;32:807-1)36.8 (1.)]TJ
-2.175 -1.25 Td
[(36.)-875.1 (Streiner DL, Norman GR. Health measurement scales. )54.8 (A)-220.1 (practical)]TJ
2.175 -1.25 Td
(guide to their development and use. 2nd ed. Oxford: Oxford)Tj
T*
(Medical Publications; 1995.)Tj
-2.175 -1.25 Td
[(37.)-875.1 (Shrout PE, Fleiss JL. Intraclass correlations: Uses in assessing rater)]TJ
2.175 -1.25 Td
[(reliability)64.8 (. Psychol Bull 1979;86:420-8.)]TJ
-2.175 -1.25 Td
[(38.)-875.1 (Fitzpatrick R, Davey C, Buxton MJ, Jones DR. Evaluating )]TJ
2.175 -1.25 Td
(patient-based outcome measures for use in clinical trials. Health)Tj
-0.0298 Tw T*
[(T)69.9 (echnol Assess )-54.8 (1998;2:1-74.)]TJ
0.02499 Tw -2.175 -1.25 Td
[(39.)-875.1 (Carbone LD, Cooper C, Michet CJ, )54.8 (Atkinson EJ, O\325Fallon )17.7 (WM,)]TJ
2.175 -1.25 Td
[(Melton LJ. )54.8 (Ankylosing spondylitis in Rochester)39.7 (, Minnesota, )]TJ
T*
[(1935-1989: Is the epidemiology changing? )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw 33 41.25 Td
(1992;35:1476-82.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(40.)-875.1 (McColl E, Jacoby )54.8 (A, )17.7 (Thomas L, et al. Design and use of )]TJ
2.175 -1.25 Td
(questionnaires: a review of best practice applicable to surveys of)Tj
T*
[(health service staf)17.7 (f and patients. Health )17.7 (T)69.9 (echnol )54.8 (Assess 2001;)]TJ
0 Tw T*
(5:1-256.)Tj
0.02499 Tw -2.175 -1.25 Td
[(41.)-875.1 (Fitzpatrick R. )17.7 (The measurement of health status and quality of life)]TJ
2.175 -1.25 Td
(in rheumatological disorders. Ballieres Clin Rheumatol 1993;)Tj
0 Tc 0 Tw T*
(7:297-317.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(42.)-875.1 (W)79.9 (are JE. Preface \321 International Quality of Life )54.8 (Assessment)]TJ
2.175 -1.25 Td
(\(IQOLA\) Project. J Clin Epidemiol 1998;51:891-2.)Tj
-2.175 -1.25 Td
[(43.)-875.1 (Guillemin F)79.7 (, Challier B, Urlacher F)79.7 (,)-0.1 ( )17.7 (V)110.8 (ancon G, Pourel J. Quality of)]TJ
2.175 -1.25 Td
[(life in ankylosing spondylitis: validation of the )54.8 (Ankylosing)]TJ
T*
[(Spondylitis )54.8 (Arthritis Impact Measurement Scales 2, a modified)]TJ
T*
[(Arthritis Impact Measurement Scales Questionnaire. )54.8 (Arthritis Care)]TJ
0 Tc T*
(Res 1999;2:157-62.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(44.)-875.1 (Jenkinson C, Ruta D, Peterson S, Mowat )54.8 (A, Stradling J. Should)]TJ
2.175 -1.25 Td
(respondents be allowed to nominate new areas at follow-up in )Tj
T*
[(individualised quality of life assessment? )54.8 (An evaluation of two)]TJ
T*
(scoring methods using the Patient Generated Index \(PGI\) [abstract].)Tj
T*
(Qual Life Res 1998;7:612.)Tj
-2.175 -1.25 Td
[(45.)-875.1 (Macduf)17.7 (f C, Russell E. )17.7 (The problem of measuring change in )]TJ
2.175 -1.25 Td
(individual health-related quality of life by postal questionnaire: use)Tj
T*
(of the patient-generated index in a disabled population. Qual Life)Tj
0 Tc T*
(Res 1998;7:761-9.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(46.)-875.1 (Haywood KL, Garratt )54.8 (AM, Jordan K, Dziedzic K, Dawes PT)73.9 (.)]TJ
2.175 -1.25 Td
(Disease-specific patient-assessed measures of health outcome in)Tj
T*
[(ankylosing spondylitis: reliability)64.8 (, validity and responsiveness.)]TJ
0 Tc T*
(Rheumatology 2002;41:1295-302.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(47.)-875.1 (Haywood KL, Garratt )54.8 (AM, Dziedzic K, Dawes PT)73.9 (. Generic)]TJ
2.175 -1.25 Td
(measures of health-related quality of life in ankylosing spondylitis:)Tj
T*
[(reliability)64.8 (, validity and responsiveness. Rheumatology)]TJ
0 Tc 0 Tw T*
(2002;41:1380-7.)Tj
ET
0 0 0 0 scn
431 777 126 -27 re
f*
428 770 130 -25 re
f*
/CS0 CS 0 0 0 1 SCN
54 54 m
558 54 l
S
BT
0 0 0 1 scn
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 54.5 35.9844 Tm
[(Haywood, et al: Patient Generated Index in )17.7 (AS)]TJ
0 Tc 0 Tw 61.4375 -0.0313 Td
(773)Tj
ET
0 0 0 0 scn
/GS0 gs
109.22 59.09 396.48 -10.84 re
f*
0.5 w
109.22 59.09 396.48 -10.84 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_2 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2003. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_3 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
64 0 obj
<>
endobj
55 0 obj
<>
endobj
92 0 obj
<>
endobj
118 0 obj
<>
endobj
54 0 obj
<>
endobj
86 0 obj
<>stream
H{PSrC@]W""hY_ ZTT%H G @䱢Jj}+nbݮ2nm??33}|3spquæ7n]& ˶I¸wcpf
M0sl'8,q$.:2